Lidocaine with ketamine in posterior spine fusion

Intravenous lidocaine infusion with single low-dose ketamine as an adjuvant to general anesthesia in posterior spine fusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202103785412583

Enrollment

Registered

2021-03-17

Start date

2021-03-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

LK Group

N Group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 60 adult patients aged between 18 - 65 years old, undergoing elective two or more levels of lumbar posterior spine fusion under general anesthesia will be enrolled in this study. Inclusion criteria include patients of both genders with American Society of Anesthesiologists (ASA) physical status I/II.

Exclusion criteria

Exclusion criteria: Known hypersensitivity to lidocaine or ketamine, pregnancy, severe renal disorder, hepatic dysfunction, cardiac arrhythmias, severe cardiac or pulmonary disease, increased intraocular pressure, history of psychiatric disorders, epilepsy, history of alcohol or drug abuse, patients receiving beta-blockers or antiarrhythmics, uncontrolled diabetes or hypertension, and patients unable to operate patient-controlled analgesia (PCA) pump.

Design outcomes

Primary

Measure	Time frame
The total intraoperative and postoperative opioid consumption and numeric pain scale.	—

Secondary

Measure	Time frame
Sedation score, i.v. rescue analgesic, PONV and pruritis.	—

Countries

Egypt

Contacts

Public ContactMostafa Mansour Houssein

Assistant professor of anesthesia and intensive care Faculty of medicine Ain Shams university

mostafa_mansour361@hotmail.com00201093322145

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026